News About: Pharm. Industry
KPMA pushes forward with survey on rebate-suspicious companies
The survey over rebate-suspicious companies, which has been postponed due to the government’s announcement of pharmaceutical industry’s promotional policy and certification of innovative pharmaceutical companies, is e...
Adjustment period changed to ‘2 years’ in market price system
The implementation date of the revised market price system is expected to start in the first half of 2018.
The Ministry of Health and Welfare recently gave an administrative notice of the ‘Partial Amendment to the Ph...
Which company did well over launching new drugs in first half?
When it comes to new drug launches made by multinational pharmaceutical companies in the first half of the year, Boehringer Ingelheim Korea and Lilly Korea were known to lead, and the most common one was anticancer dr...
Innov. drug companies make annual sales of KRW 414 million per person
The average annual sales per employee working in innovative pharmaceutical companies was KRW 414 million, the foreign pharmaceutical companies Sanofi-Aventis Korea was aggregated to make the most, KRW 760 million, in ...
KSHP’s investigation on multinational pharmaceutical companies’ out-of-stock crisis
Over the multinational pharmaceutical companies’ out-of-stock crisis, the Korean Society of Health-system Pharmacists(KSHP) has shown a move to conduct investigation.
The KSHP(President Kwang-sup Lee) plans to conduc...
“41 pharmaceutical companies poured KRW 5.6 billion into symposiums”
The Korea Pharmaceutical Manufacturers Association’s member companies were aggregated to support funds of KRW 5.6 billion on domestic and foreign symposiums.
According to the analysis result of the companies’ suppor...
Salesmen decrease while demands on R&D, manufacturing personnel increase
It was observed a manpower shortage on R&D, manufacturing and quality professionals is getting worse in the pharmaceutical industry.
Moreover, along with the Hanmi Pharm’s jackpot technology exports and the pharmace...
Status on Trajenta’s patent suits, will it lead to ‘composition’ too?
The Boehringer Ingelheim’s antidiabetic which recorded KRW 26.1 billion outpatient prescriptions only in the first half of the year, ‘Trajenta’ has become a target of many pharmaceutical companies to nullify its paten...
Innovative pharmaceutical companies earn KRW 102 out of KRW 1,000 products
I was analyzed innovative pharmaceutical companies earned KRW 102 out of selling products of KRW 1,000 products last year, and Pharma Research Products and Celltrion earned more than KRW 400.
According to the Yakup S...
Only 10 innovative pharmaceutical companies spent over 10% on R&D
It was surveyed there were only less than 10 companies which exceeded 10% in the R&D expense rate against sales among innovative pharmaceutical companies.
Moreover, it was observed there were the total 4 innovative ...
